- Describe your topic.
- What is the place of topical PDE4 Inhibitors in atopic dermatitis treatment?
- Describe why this topic is important.
- Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 (PDE4) activity, which is associated with production of pro-inflammatory mediators. Although topical agents available for the treatment of AD are generally well tolerated, topical corticosteroids may cause cutaneous and systemic side effects when used inappropriately, and topical calcineurin inhibitors carry a boxed warning for malignancy risk. There is a need for new topical treatment options without such safety concerns. One such option may be topical PDE4 inhibitors. The first new class of topical treatments of atopic dermatitis is topical Crisaborole, a Phosphodiesterase – 4 inhibitor. It is important to know the overall safety and efficacy of this class of drugs.
- Tell us why you are suggesting this topic.
- The American Academy of Dermatology will soon be updating its guideline for the management of atopic dermatitis
- Target Date.
- 2018-11-01
- Describe what you are doing currently and what you are hoping will change because of a new evidence report.
- The evidence report would help the academy to decide if treatment recommendations should be developed on PDE 4 inhibitors. Our previous guideline did not provide recommendations around PDE4 inhibitors.
- How will you or your group use the information from a new evidence report?
- The American Academy of Dermatology will soon be updating our guideline for the management of atopic dermatitis. We plan to use a new evidence report to draft evidence-based recommendations for the treatment of atopic dermatitis using topical PDE4 inhibitors.
- How would you or your group plan to disseminate information from the report? Who would you plan to disseminate it to?
- The evidence report from EPC would be reviewed by nominated workgroup physicians in deciding treatment recommendations on PDE4 inhibitors for atopic dermatitis guideline.
- Do you know of organizations that could use an evidence report to change clinical practice? Are you a part of, or have you been in contact with, any organizations that might implement the research findings of an evidence report?
- Information About You: (optional)
-
- Provide a description of your role or perspective.
- Professional Society
- If you are you making a suggestion on behalf of an organization, please state the name of the organization.
- American Academy of Dermatology
- Please tell us how you heard about the Effective Health Care Program.
